All news
Karnataka High Court Quashes Drug Price Control Prosecution Against MedPlus Over Rs 1.12 Excess
News2 min read

Karnataka High Court Quashes Drug Price Control Prosecution Against MedPlus Over Rs 1.12 Excess

L

LawWorld

The Karnataka High Court quashed criminal proceedings against MedPlus and its officials in C.C. No. 7712/2019. A single bench of Justice S. Vishwajith Shetty passed the oral order on November 13, 2026. The petitions invoked Section 482 of the Code of Criminal Procedure to seek quashing of the prosecution arising from an August 23, 2016 retail sale.

According to the complaint, the prosecution alleged short supply of one tablet to a customer at the MedPlus outlet. It also alleged excess collection of Rs 1.12 from that customer in the same transaction. The complaint treated the short supply and the small excess as a violation of price-control law.

Billing error, not price violation

Justice Shetty examined the complaint against Clause 26 of the Drugs (Price Control) Order, 2013. That clause deals with sale of a formulation above the ceiling price or the printed label price. The bench said the facts placed before it did not constitute such a sale. In the bench's view, a billing error involving one tablet and Rs 1.12 could not be read as charging above the controlled price.

For punishment, the prosecution relied on Section 7(1)(a)(ii) of the Essential Commodities Act, 1955. That section provides punishment for contravention of an order made under the Act, including the 2013 Order. The bench held the essential ingredient of the offence under Clause 26 read with that section was not made out on these facts. It therefore allowed the petitions filed by the company and the officials named as accused.

On that finding, the bench quashed the proceedings pending before the trial court. The bench treated the dispute as a retail billing error rather than a price-control violation. The relief covers both the company and the officials who had approached the Court for quashing. They will no longer face trial in the complaint based on the 2016 transaction.